Alexion Pharmaceuticals (14)
Browse by Contract Category
Contracts
-
Description of Securities of the Registrant
(Filed With SEC on February 8, 2021)
-
AGREEMENT AND PLAN OF MERGER dated as of December12, 2020 among ASTRAZENECA PLC, DELTA OMEGA SUB HOLDINGS INC., DELTA OMEGA SUB HOLDINGS INC. 1, DELTA OMEGA SUB HOLDINGS LLC 2 and...
(Filed With SEC on December 14, 2020)
-
Confidential Release and Separation Agreement by and between Anne-Marie Law and Alexion Pharmaceuticals, Inc. effective September 26, 2020
(Filed With SEC on October 29, 2020)
-
Confidential Settlement and License Agreement, dated as of May 28, 2020, by and between Alexion Pharmaceuticals, Inc., Alexion Pharma International Operations Unlimited Company...
(Filed With SEC on June 3, 2020)
-
Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. and Odyssey Merger Sub Inc
(Filed With SEC on May 7, 2020)
-
Alexions Non-Employee Director Nonqualified Deferred Compensation Plan
(Filed With SEC on February 4, 2020)
-
Description of Securities of the Registrant
(Filed With SEC on February 4, 2020)
-
Contingent Value Rights Agreement dated as of January 28, 2020 among Alexion Pharmaceuticals, Inc. and Computershare Inc
(Filed With SEC on January 28, 2020)
-
Employment Agreement, dated as of September 17, 2019, by and between Aradhana Sarin and Alexion Pharmaceuticals, Inc
(Filed With SEC on October 23, 2019)
-
Agreement and Plan of Merger, dated October 15, 2019, by and among Alexion, Beagle Merger Sub, Inc. and Achillion
(Filed With SEC on October 16, 2019)
-
Form of 2017 Incentive Plan Restricted Stock Unit Agreement for Director Annual Grant
(Filed With SEC on July 24, 2019)
-
Form of 2017 Incentive Plan Restricted Stock Unit Agreement for Director Fees
(Filed With SEC on July 24, 2019)
-
Employment Agreement, dated June 5, 2017, by and between Anne-Marie Law and Alexion Pharmaceuticals, Inc
(Filed With SEC on April 25, 2019)
-
Employment Agreement, dated as of June 5, 2017, by and between John J. Orloff and Alexion Pharmaceuticals, Inc
(Filed With SEC on April 25, 2019)